Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–380 of 380 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Antipsychotics Clear all
Completed Phase 3 Interventional

A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)

NCT01192867
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, RO4917838, Antipshychotics (Standard of Care)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
27
States / cities
Little Rock, Arkansas • Anaheim, California • Cerritos, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 27, 2026, 1:06 PM EDT
Terminated Not applicable Interventional Results available

Study of Aripiprazole to Reduce Medical Risks in Bipolar Disorder

NCT00665444
View directory record Official record
Conditions
Bipolar Disorder, Metabolic Syndrome
Interventions
Aripiprazole
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 22, 2017 · Synced Oct 27, 2026, 1:06 PM EDT
Not yet recruiting Not applicable Interventional

Evaluating the Impact of Ketogenic Therapy on Symptom Severity and Metabolic Side Effect Profile Among Individuals Living With Bipolar Disorder in A Rural Southern Catchment Area

NCT07570875
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Ketogenic foodstuffs, Standard of Care Oral antipsychotics, Standard of care long acting injectable medication for bipolar disorder
Dietary Supplement · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Montgomery, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 27, 2026, 1:06 PM EDT
Completed Phase 3 Interventional Results available

Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults

NCT02610868
View directory record Official record
Conditions
Sialorrhea
Interventions
MYOBLOC
Drug
Lead sponsor
Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
26
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Loma Linda, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 27, 2026, 1:06 PM EDT
Completed Not applicable Interventional Results available

The PACE/PACENET Behavioral Health Laboratory Project

NCT02440594
View directory record Official record
Conditions
Depression
Interventions
Enhanced BHL Program Services, Standard BHL Program Services
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
65 Years and older
Enrollment
2,432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 27, 2026, 1:06 PM EDT
Completed Not applicable Interventional

An Exploratory, Double-arm, 8-week Study to Explore the Feasibility and Acceptability of Abbreviated Treatment with CT-156 in People with Schizophrenia.

NCT06486948
View directory record Official record
Conditions
Schizophrenia
Interventions
CT-156
Device
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 27, 2026, 1:06 PM EDT
Completed Not applicable Interventional Results available

Biosignatures of Latuda for Bipolar Depression

NCT02239094
View directory record Official record
Conditions
Bipolar Depression
Interventions
Lurasidone (Latuda)
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 27, 2026, 1:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Akathisia (Restless Legs Syndrome) in People With Schizophrenia and Mental Retardation

NCT00065286
View directory record Official record
Conditions
Akathisia
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 1999
U.S. locations
2
States / cities
Morganton, North Carolina • University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 27, 2026, 1:06 PM EDT
Terminated Early Phase 1 Interventional

The Use of Sensory or Motor Cues Using Electrical Stimulation to Reduce Gait Freezing in Patients With Parkinson Disease

NCT00762814
View directory record Official record
Conditions
Parkinson Disease
Interventions
Gait tests with and without the use of a tactile sensory cue (electrical stimulation using a TENS unit)
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 27, 2026, 1:06 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Effects of Atypical Antipsychotics on Brain Function in Children and Teens With Conduct Disorders

NCT01867398
View directory record Official record
Conditions
Conduct Disorder, fMRI
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
10 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 27, 2026, 1:06 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)

NCT01825798
View directory record Official record
Conditions
Overweight, Autism Spectrum Disorder
Interventions
Metformin, Placebo
Drug
Lead sponsor
Holland Bloorview Kids Rehabilitation Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Columbus, Ohio • Pittsburgh, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 27, 2026, 1:06 PM EDT
Completed Phase 4 Interventional Results available

Quetiapine Augmentation for Treatment-resistant PTSD

NCT00292370
View directory record Official record
Conditions
Combat Disorders, Stress Disorders, Post-Traumatic
Interventions
Open Label (OL) Paroxetine, Placebo, Quetiapine
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Oct 27, 2026, 1:06 PM EDT
Completed Early Phase 1 Interventional

Quetiapine Augmentation of PE Therapy for the Treatment of Co-occurring PTSD and Mild Traumatic Brain Injury

NCT04280965
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Quetiapine Fumarate, Standard of care meducations
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 27, 2026, 1:06 PM EDT
Completed Phase 2 Interventional Results available

12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression

NCT02363738
View directory record Official record
Conditions
Bipolar Depression
Interventions
Infliximab, Saline
Drug · Other
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 27, 2026, 1:06 PM EDT
Completed Phase 4 Interventional Results available

Comparative Effectiveness Study for Bipolar Disorder

NCT01331304
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium, Quetiapine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 68 Years
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
Birmingham, Alabama • Stanford, California • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Oct 27, 2026, 1:06 PM EDT
Completed Not applicable Interventional

Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia

NCT00161031
View directory record Official record
Conditions
Schizophrenia
Interventions
Atomoxetine
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Baltimore, Maryland • Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 27, 2026, 1:06 PM EDT
Completed Phase 3 Interventional

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

NCT01714661
View directory record Official record
Conditions
Schizophrenia, Impaired Cognition
Interventions
EVP-6124, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
38
States / cities
Tucson, Arizona • Anaheim, California • Bellflower, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 27, 2026, 1:06 PM EDT
Completed No phase listed Observational

Treatment Study of Frontotemporal Dementia

NCT00088751
View directory record Official record
Conditions
Frontotemporal Lobar Degeneration
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
45 Years to 95 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 27, 2026, 1:06 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication

NCT05628103
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-363856
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
25
States / cities
Anaheim, California • Bellflower, California • Culver City, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 27, 2026, 1:06 PM EDT
Completed Phase 4 Interventional

Antipsychotic Response in Schizophrenia

NCT00018668
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone, Olanzapine, Quetiapine
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 27, 2026, 1:06 PM EDT